Financial Data and Key Metrics Changes - Operating expenses net for 2025 decreased to approximately $13.8 million from approximately $22 million in 2024, reflecting a significant reduction in costs [17] - Revenues for 2025 totaled approximately $3.9 million, down from approximately $5.6 million in the previous year, primarily due to lower revenue from AgPlenus [22] - The net loss for 2025 was approximately $7.8 million compared to approximately $18.1 million in the same period last year, indicating improved financial performance [31] Business Line Data and Key Metrics Changes - R&D expenses for 2025 were approximately $8 million, a decrease of approximately $4.5 million compared to 2024, mainly due to reduced expenses in Biomica, Casterra, and AgPlenus [24] - Sales and marketing expenses for 2025 were approximately $1.5 million, down from approximately $2 million in the previous year, reflecting cost-cutting measures [25] - AgPlenus continues to apply ChemPass AI for the development of novel herbicides and fungicides, with expectations for growth through collaborations with Bayer and Corteva [14] Market Data and Key Metrics Changes - Casterra Ag ceased operations in Kenya and is focusing on the Brazilian market, leading to an impairment of approximately $2.2 million related to seed inventory [19] - The agricultural market has seen a decline in demand, affecting Casterra's operations, but there is an expectation of increased collaboration opportunities as the need for innovation grows [41] Company Strategy and Development Direction - The company has shifted its focus to two high-impact markets: human health and agriculture, utilizing the ChemPass AI platform for drug development and ag chemicals [8] - The strategic transformation includes discontinuing non-core activities and resizing the organization to enhance operational efficiency [7] - The long-term goal is to develop a proprietary product pipeline while becoming the partner of choice for small molecule discovery and optimization [15] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of strategic partnerships and collaborations to enhance the company's capabilities and market position [12] - The company expects to maintain sufficient cash flow for operations for at least a year and a half, even without additional financial transactions [36] - Management anticipates significant future catalysts, including technology collaborations and partnerships with larger biotech and ag chemical companies [39][41] Other Important Information - The company recognized a gain on the sale of Lavie Bio's assets, amounting to approximately $6.4 million, which contributed to the income from discontinued operations [31] - As of December 31, 2025, the company held approximately $13 million in cash equivalents and short-term bank deposits [21] Q&A Session Summary Question: Can you speak to the terms of the BMC128 license agreement with Lishan Pharmaceuticals? - The agreement includes milestone payments based on the advancement of BMC128 and revenue sharing from the end product [34] Question: Can you speak to the magnitude of cash potentially coming in from Lavie Bio and Biomica? - Expected cash from Lavie Bio and Biomica will satisfy operational needs for at least mid-next year, with sufficient cash for over a year and a half [36] Question: What are the expected investor catalysts over the coming 12 months? - Anticipated catalysts include technology collaborations with companies like Google, additional agreements with biotech and pharma companies, and collaborations with ag chemical companies [39][41]

Evogene (NasdaqCM:EVGN) Q4 2025 Earnings call March 05, 2026 09:00 AM ET Company ParticipantsOfer Haviv - President and CEOYaron Eldad - CFOOperatorWelcome to Evogene's Q4 2025 results conference call. All participants are at present in listen-only mode. Following management's formal presentation, we will open the question-and-answer session. You may send questions via chat. Please type your name and company before your question. As a reminder, this conference is being recorded March 5, 2026. Before we begi ...

Evogene (NasdaqCM:EVGN) Q4 2025 Earnings call March 05, 2026 09:00 AM ET Speaker1Welcome to Evogene's fourth quarter 2025 results conference call. All participants are at present in listen-only mode. Following management's formal presentation, we will open the question-and-answer session. You may send questions via chat. Please type your name and company before your question. As a reminder, this conference is being recorded March 5, 2026. Before we begin, I would like to caution that certain statements made ...